Intellia Therapeutics Stock (US45826J1051): Wedbush Sticks To Neutral Rating After HAE Rally

After a sharp rally on new Phase 3 HAE data, Wedbush reaffirmed its Neutral rating and $12 price target on Intellia Therapeutics, keeping a cautious stance despite fresh clinical momentum.

Responsible: ad hoc news Stocks & Analysis Desk. Reviewed prior to publication on June 16, 2026 at 7:50 PM ET. Details in the imprint.

Intellia Therapeutics has drawn fresh attention from Wall Street after a powerful move in its share price on new hereditary angioedema (HAE) data, but at least one key analyst is not changing course. On June 15, 2026, Wedbush analyst David Nierengarten reiterated a Neutral rating on Intellia Therapeutics and maintained a $12.00 price target, signaling a wait-and-see stance despite mounting enthusiasm around the company’s gene-editing pipeline.

The reaffirmed rating comes on the heels of a more than 20 percent jump in Intellia’s stock, driven by additional positive Phase 3 results from the HAELO trial of its CRISPR-based therapy lonvoguran ziclumeran (lonvo-z) for HAE and a peer-reviewed publication that further supported the program’s profile. While the stock recently traded around $12.64 per share in the U.S. market according to separate pricing data, Wedbush’s $12.00 target underlines that at least this analyst does not yet see a clear case for a sustained re-rating of the company’s valuation.

Wedbush reaffirms Neutral on Intellia despite data-driven rally

According to a June 15, 2026 note summarized by GuruFocus, Wedbush’s David Nierengarten reiterated his Neutral rating on Intellia Therapeutics, keeping a 12-month price target of $12.00 per share. The report highlights that this stance effectively treats the stock as fairly valued in the near term, given that the target is close to the prevailing market price referenced around $13.06 in the same overview. The analysis further notes that GuruFocus calculates a proprietary GF Value of $20.77 for Intellia, implying the shares could be approximately 37 percent undervalued relative to that metric, but this valuation framework is distinct from the Wedbush rating itself and reflects a model-based view rather than a formal change in sell-side opinion.

Wedbush’s decision to maintain a Neutral rating following the latest HAE data suggests that, from this analyst’s perspective, positive clinical momentum is at least partly reflected in the current share price. The Neutral designation typically indicates that the analyst does not see a compelling risk-reward skew either to the upside or downside over the coming 12 months, especially when the target sits near the recent trading range. While the GuruFocus commentary points to a GF Value that is higher than the market price, Wedbush’s unchanged target underscores that not every valuation tool is pointing in the same direction, and that risk factors, competitive dynamics, or execution questions may still weigh on the analyst’s overall view.

This divergence between a model-derived fair value and a more conservative equity research target is not unusual for development-stage biotechnology companies. For Intellia, much of the prospective value still depends on successful late-stage trials, regulatory outcomes, commercial execution, and the broader reception of CRISPR-based therapies. Against that backdrop, Wedbush’s stance appears to reflect a balance between acknowledging the promise of Intellia’s gene-editing platform and recognizing the uncertainties that remain on the path to sustainable revenue generation.

The reaffirmed Neutral rating is particularly notable given the scale of the stock’s recent move. Quiver Quantitative data indicated that Intellia’s shares jumped about 23 percent on a recent trading day after the company shared additional Phase 3 information on its HAE program and a high-profile, peer-reviewed publication helped bolster confidence in the therapy’s efficacy and safety profile. Zacks likewise reported that Intellia’s stock rose 23.2 percent after the release of the new Phase III HAELO study data, confirming that the rally was not a marginal move but a substantial repricing event in the near term. Wedbush’s choice not to upgrade the stock or significantly raise the target following such a rally underscores the firm’s cautious posture.

Fresh Phase 3 HAELO data and publication fuel investor optimism

The rally that set the stage for Wedbush’s latest rating decision has been rooted in clinically significant developments in Intellia’s HAE program. According to a summary of investor commentary, Intellia presented additional Phase 3 HAELO results for lonvoguran ziclumeran at the EAACI 2026 congress, accompanied by a simultaneous publication of the full study report in a major peer-reviewed medical journal. The HAELO trial had already met its primary endpoint, and the new data reinforced key efficacy metrics: an 87 percent reduction in mean monthly HAE attacks compared with placebo during weeks 5 to 28 of the trial, with 62 percent of treated patients remaining attack-free and off preventive therapy during that six-month efficacy window, versus 11 percent in the placebo group.

These numbers are meaningful for patients with hereditary angioedema, a rare and potentially life-threatening condition characterized by unpredictable swelling attacks. The data suggest that a substantial proportion of patients might achieve sustained freedom from attacks and chronic preventive regimens after treatment with lonvo-z, an outcome that could reshape expectations for one-time or infrequently dosed gene-editing therapies in this indication. Market observers have noted that such robust efficacy, if confirmed by regulators and ultimately reflected in real-world use, has the potential to justify premium pricing and strong uptake in the HAE community, which in turn supports a more optimistic long-term revenue outlook for Intellia.

The peer-reviewed publication accompanying the EAACI 2026 presentation is also a nontrivial milestone. For cutting-edge modalities such as in vivo CRISPR therapies, publication in a reputable journal often serves as an external validation of the trial’s design, conduct, and statistical analysis. This can help build credibility not only with investors but also with clinicians, regulators, and payers who will ultimately assess the therapy’s risk-benefit profile. According to Quiver Quantitative’s summary, the combination of additional Phase 3 data, scientific publication, and the potential for a streamlined regulatory path contributed significantly to the surge in Intellia’s share price, alongside possible momentum-driven trading and short covering.

Coverage from other outlets has echoed the view that the new HAELO data marked an important inflection point for Intellia. Zacks noted that the additional positive Phase III results from the HAE study drove the shares higher by just over 23 percent in the preceding session, emphasizing that the market response reflected a reappraisal of the company’s pipeline strength following confirmation of the program’s late-stage performance. While specific regulatory timelines and submission plans remain subject to the company’s formal guidance and future announcements, investors generally interpret a successful Phase 3 trial in a serious rare disease as a critical de-risking event, particularly for a platform that could be extended to other targets over time.

At the same time, the surge in Intellia’s share price inevitably raises questions about how much of this positive news is already reflected in the current valuation. Development-stage biotech stocks, especially those at the forefront of new technologies, are prone to sharp price swings as market participants recalibrate probabilities of success, peak sales assumptions, and competitive positioning based on incremental data. The Wedbush Neutral rating, maintained immediately after such a move, implicitly suggests that, from this analyst’s vantage point, the recent rally may have brought the stock closer to what they consider a balanced risk-reward level rather than leaving a large margin for error.

Stock performance and valuation snapshots after the move

As the dust settles from the post-data rally, several valuation snapshots offer a sense of where Intellia stands in the eyes of different market observers. The GuruFocus note relaying Wedbush’s rating indicated that the analyst’s $12.00 price target was close to a contemporaneous share price of roughly $13.06, reinforcing the view that the stock is near what Wedbush considers fair value in the near term. By contrast, the proprietary GF Value calculated by GuruFocus was cited at about $20.77, implying that, on that metric, the stock could be about 37.1 percent undervalued versus its market price at the time.

Other data providers have reported slightly different spot prices, reflecting normal intraday moves and pricing source variations. Financhill, for example, lists a current Intellia Therapeutics stock price of $12.64 and notes that, based on its own historical-data-driven model, the stock could be forecast to rise to $15.13 over the next 52 weeks. This type of quantitative forecast, while not a substitute for fundamental analysis, provides an additional lens through which some investors gauge potential upside, especially when cross-checking it against sell-side targets and intrinsic value estimates from platforms like GuruFocus.

Investing.com has also documented the market’s reaction to the HAE news, reporting that Intellia’s stock surged by about 21.5 percent in after-hours trading to reach $14.71 at one point as enthusiasm spread following the updated data and intensifying buying interest. Together, these data points illustrate both the magnitude of the recent move and the range of valuation opinions now circulating around the stock. At one end, a cautious analyst target sits near the low teens; at the other, model-based fair value estimates and near-term quantitative forecasts point to levels in the mid-teens or above, though each of these approaches carries its own assumptions and limitations.

For U.S. retail investors tracking Intellia on Nasdaq under the ticker NTLA, the key question is how to interpret this mix of signals. The stock’s sharp move following the HAELO data, combined with a maintained Neutral rating from Wedbush and a GF Value suggesting undervaluation, highlights the tension between near-term sentiment and longer-term expectations. While some model frameworks see room for upside from current levels, the sell-side stance underscores that execution, regulatory decisions, and competitive dynamics across the broader gene-editing landscape remain crucial variables that could influence the trajectory of Intellia’s shares over time.

Overall, the latest developments position Intellia as a high-profile, higher-risk name within the U.S. biotech universe, with significant potential tied to its CRISPR-based platform but also the typical uncertainties inherent to late-stage drug development. Investors watching the stock may pay close attention to future updates on regulatory interactions for the HAE program, progress in other pipeline indications, and any shifts in analyst sentiment as new information becomes available.

Intellia Therapeutics at a glance

• Name: Intellia Therapeutics, Inc. (NTLA)
• Industry: Biotechnology (gene-editing therapies)
• Headquarters: Cambridge, Massachusetts, United States
• Core markets: Rare diseases and genetic disorders treated with in vivo CRISPR-based therapies
• Revenue drivers: Collaboration revenues and prospective product sales from gene-editing candidates such as HAE therapies
• Listing: Nasdaq Global Select Market, ticker symbol NTLA
• Trading currency: US dollar (USD)

This article was created with a.i. assistance and editorially reviewed. Not investment advice, not a buy or sell recommendation. Trading in securities carries risks up to the total loss of capital.